| Name | Title | Contact Details |
|---|
AWAK is a patient-centric medical technology company with a mission to enhance the lives of dialysis patients and their caregivers by providing solutions to deliver better outcomes along with improving their quality of life.
We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we`ve rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow® System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life`s work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions.
Atlantic Imaging Group is a Cedar Knolls, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medicorp Inc is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LENSAR, Inc. is a global leader in next-generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR`s proprietary Augmented Reality technology -- reconstructed 3-D imaging, measurement, and guidance system -- offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery, and efficient lens fragmentation that can reduce, and potentially eliminate phaco energy. The LENSAR Laser System also offers the industry`s smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms. The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only